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How lymphoid cell fate is orchestrated in early hematopoietic progenitors remains poorly understood. In this
issue of Immunity, Satoh et al. (2013) show that the chromatin remodeler Satb1 promotes lymphocyte differ-
entiation in both young and aged stem cells.Adaptive and innate immune cells
develop from long-term hematopoietic
stem cells (LT-HSCs) that are multipotent
and have the ability to self-renew. As cells
travel progressively along hematopoietic
highways, they acquire new lineage-
specific transcription signatures and
extinguish alternative programs of gene
expression. Specifically, LT-HSCs give
rise to multipotent progenitors (MPPs),
which remain multipotent but lose the
ability to self-renew. MPPs, in turn,
readily generate lymphoid and myeloid
progenitors, collectively called lymphoid-
primed MPPs (LMPPs), which no longer
retain erythrocyte or megakarytocyte
potential.
LMPPs give rise to the B, T, NK, plas-
macytoid dendritic and myeloid cell
lineages through distinct intermediates.
Two of these intermediates, the common
lymphoid progenitor (CLP) and granulo-
cyte-macrophage progenitor (GMP),
have been particularly well characterized.
GMPs yield macrophages or granulo-
cytes whereas CLPs give rise to the
plasmacytoid dendritic, NK, B, or T cell
lineages. The CLP compartment is
composed of at least two populations
that display distinct developmental
properties, one pool of cells that show
the full array of lymphoid potential and
another prone to adopt a B cell trajectory.
The journey from the non-B cell
biased CLP to the T and NK cell lineages
involves yet another intermediate called
the early T cell progenitor (ETP). ETPs
display developmental potential for the
T, myeloid, dendritic, and NK cell
lineages.
Stem cell function changes during
ontogeny and with aging (Rossi et al.,
2008). HSCs from fetal tissues have
a greater capacity to differentiate into
lymphoid cells than HSCs derived from
young adult mice. Likewise, HSCs iso-lated from young adult mice more readily
give rise to lymphoid cells compared
with HSCs from aged mice. Aged
HSCs also differ from young HSCs in
their ability to home, to reconstitute
irradiated recipient mice, and to give rise
preferentially to myeloid cells at the
expense of lymphoid cell fate. Indeed,
the skewing of aged HSCs toward the
myeloid compartment correlates with
the reduced numbers of lymphoid
progenitors and elevated numbers of
myeloid precursors observed in aged
mice. The differences in the develop-
mental potential of young versus aged
HSCs are cell autonomous and involve
both the repression of genes associated
with lymphoid specification, as well as
the activation of loci closely associated
with the myeloid cell lineage.
Priming of transcription signatures is
initiated as early as the HSC cell stage
and may reflect the requirement for
HSCs to give rise to the wide array of
cells that ultimately establish the adult
adaptive and innate immune system.
Transcripts readily detectable in HSCs
are associated with both myeloid- and
lymphoid-specific programs of gene ex-
pression (Mercer et al., 2011). Conspic-
uous among these are the transcription
factors PU.1, Ikaros, and E2A. PU.1
proteins that contain an ETS-related
DNA binding domain, whereas Ikaros
proteins are characterized by zinc-
finger-containing DNA binding domains.
The E2A proteins consist of two iso-
forms, E12 and E47. E12, and E47 are
members of the helix-loop-helix family
of proteins.
Ikaros was the first transcriptional
regulator shown to orchestrate the
development of the lymphoid branch of
hematopoiesis (Georgopoulos et al.,
1994). Ikaros-deficient HSCs display a
block in their ability to self-renew, andImmunity 3Ikaros is required to induce the ex-
pression of the cytokine receptor Flt3
and to promote the developmental pro-
gression toward the LMPP cell stage.
In contrast, PU.1 expression is required
to promote HSC differentiation toward
both the myeloid and lymphoid cell line-
ages and appears dose dependent
(Scott et al., 1994). High abundance of
PU.1 promotes myeloid cell fate whereas
low levels of PU.1 are associated with
development toward the B cell lineage.
Moreover, PU.1 expression in B-lineage
progenitors is modulated by the ex-
pression of yet another transcriptional
regulator, Gfi1. Mice deficient for Gfi-1
exhibit enhanced myeloid development
at the expense of differentiation toward
the B cell fate. Gfi-1 expression, in turn,
is regulated by Ikaros, establishing a
regulatory circuitry that underpins the
mechanism by which the B versus
myeloid cell fate is determined. Like
Ikaros, the E2A proteins act in HSCs to
maintain the HSC pool, to promote the
developmental progression toward the
LMPP compartment, and to establish
lymphoid cell fate (Dias et al., 2008;
Yang et al., 2008; Semerad et al.,
2009). Lastly, establishment of the
lymphocyte cell fate is closely associated
with the expression of the cytokine
receptors Flt3 and interleukin-7Ra
(IL-7Ra). Consistent with this pattern,
Flt3 expression is regulated by the com-
bined activities of PU.1 and Ikaros,
whereas PU.1 acts in concert with E2A
to modulate the expression of IL-7Ra.
Here, Satoh et al. (2013) introduce
a new participant, special AT-rich
sequence-binding protein (Satb1), to the
set of transcriptional regulators that
regulate lymphoid cell fate. Satb1 is an
intriguing protein that promotes large-
scale genomic interactions, which induce
cage-like structures within the nuclei8, June 27, 2013 ª2013 Elsevier Inc. 1081
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Figure 1. Roles of Satb1 in Early Hematopoiesis
Indicated are hematopoietic compartments that promote development toward the erythroid, myeloid,
and B and T cell lineages. Transcription factors that control developmental checkpoints are shown. The
developmental transitions involving Satb1 in early hematopoiesis are indicated in red. HSC indicates
the hematopoietic stem cell compartment. MPP refers to multipotent progenitors. The lymphoid-primed
multipotent progenitors compartment is indicated by LMPP. GMP refers to the granulocyte-macrophage
progenitor compartment. MEP refers to the megakaryocytic-erythroid progenitor compartment. CLP
represents the common lymphoid progenitor population. ETP refers to the early thymocyte progenitor
compartment.
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Previewsof activated T-lineage cells (Alvarez
et al. 2000). Previous studies have
demonstrated that Satb1 promotes the
differentiation of embryonic stem cells
(ESCs) by antagonizing the expression
of genes encoding for regulators of
stem cell identity such as Nanog (Savar-
ese et al., 2009). A recent study has
revealed that Satb1 also maintains the
HSC stem cell pool (Will et al., 2013)
(Figure 1). For example, Satb1-deficient
mice displayed loss of quiescence
and increased levels of lineage com-
mitment. Satb1 also plays a role in
T cell-lineage commitment, promoting
the differentiation and survival of
early T cell-lineage progenitors (Fig-
ure 1). Satoh et al. (2013) perform
experiments that confirm and extend
previous observations and provide new
and unexpected insights into the acti-
vities of Satb1. Upon transplantation,
Satb1-deficient hematopoietic progeni-
tors displayed a substantial block in
T-lineage development. The defect
was particularly pronounced in the DN
compartment and during the transition
from the DP to the SP cell
stage (Figure 1). Notably, the spleens
of recipient mice transplanted with1082 Immunity 38, June 27, 2013 ª2013 ElseSatb1-deficient hematopoietic progeni-
tors displayed significant numbers of
DP thymocytes, indicating that Satb1
expression may act to restrain aber-
rant migration of developing thymocytes
prior to maturing into SP cells. The
authors also perform a series of gain-
of-function experiments that yielded
striking outcomes. First, forced Satb1
expression either in ESCs or HSCs
substantially increased lymphocyte pro-
duction. Production of B- and T-lineage
cells was increased in cultures derived
from ESCs overexpressing Satb1.
Satb1 expression also strongly enhanced
T cell production (>5 fold) upon cultur-
ing transduced progenitors on OP9-
DL1 stromal cells. Even more impres-
sive, the production of B-lineage cells
was enhanced (up to 300-fold) upon
Satb1 overexpression in hematopoietic
precursors.
How does Satb1 exert its activity
to promote differentiation toward the
lymphocyte cell fate? Interestingly, the
transcription signatures in progenitors
overexpressing Satb1 revealed an
ensemble of cytokines typically associ-
ated with a stromal cell-specific pro-
gram of gene expression. These in-vier Inc.cluded IL-7 and kit ligand. Thus,
Satb1 may act to establish an auto-
crine loop, involving kit ligand and
IL-7, to increase the production of
lymphocytes from progenitor cells. An
interesting corollary of these findings is
that B1 but not B2 cells developed
upon ectopic expression of Satb1.
This bias likely reflects the embryonic
origin of the hematopoietic progenitors
and it would be of interest to characterize
the transcription signatures of these
cells.
Finally, Satoh et al. (2013) also show
that forced Satb1 expression rescues
the deficiency in lymphoid production in
aged HSCs. As aforementioned, it is
now well established that aged HSCs
are defective in the production of
lymphoid progeny, whereas myeloid
potential is significantly enhanced.
Interestingly, the authors found that
Satb1 expression in HSCs declines in
aged mice. This observation raised the
question of whether the decline in lym-
phoid potential in aged HSCs is ex-
plained, at least in part, by a decline in
Satb1 expression. To address this possi-
bility, Satoh et al. (2013) forced expres-
sion of Satb1 in aged HSCs. Remarkably,
the mere overexpression of Satb1 ap-
peared to restore, albeit partially, the
lymphoid capacity of aged HSCs. While
intriguing, it will be important to extend
these findings to an in vivo setting. It will
be truly exciting if expression of a single
transcription factor restores the lym-
phoid potential of aged HSCs within the
context of an organism.
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To understand the adaptations of costimulatory molecules through mammalian evolution, Forni et al.
(Forni et al., 2013) studied evolutionary selection in key costimulatory genes. Their results, presented in
this issue of Immunity, suggest that the risk of autoimmmunity is balanced against efficacy of the anti-path-
ogen immune response.To better understand the consequences
and causes of genetic selection in mole-
cules that regulate T cell responses,
Forni et al. (2013) studied the evolution
of key T cell regulatory molecules across
the 175 million years of mammalian
diversification. They examined the
APC:Tcell ligand-receptor pairs of CD80–
CD86:CD28-CTLA-4, PD-L1-PD-L2:PD-
1, ICOSLG:ICOS, Galectin-9:TIM-3,
FASLG:FAS, and CD40:CD40LG. These
regulate the strength, speed, and duration
of immune responses andwere chosen on
the basis of their importance, well-charac-
terized functions, and known structures.
Selective pressure on the genes encod-
ing the molecules that regulate immune
responses has resulted in the positive
selection of alleles that provide a survival
advantage. Forni et al. compared the
coding sequences of T cell regulatory
molecules from 39 mammalian species
and determined where selective pressure
has changed the molecules. They did this
by calculating the dN/dS ratio of non-
synonymous (dN, changes amino acid)
to synonymous (dS, doesn’t change
amino acid) changes at codons across
the length of the proteins. They identified
a small number of amino acids in nine
of the 15 T cell regulatory molecules
(CD80, CD86, CD28, PD-L1, PD-L2,
TIM-3, Galectin-9, FAS, and CD40) for
which dN/dS was significantly >1, indi-cating that the amino acid was under pos-
itive selection and thus that it provided a
selective advantage to that species.
To determine possible reasons for
selection in the coding regions of these
genes, Forni et al. mapped the positively
selected amino acids onto the crystal
structures of the proteins, represented
schematically in Figure 1. They showed
‘‘hot spots’’ of positive selection, including
the CD28 transmembrane domain, the
CD80 IgV-like domain (IgV), the CD86
IgC-like (IgC) domain, the stalk and trans-
membrane domains, the PD-L1 and PD-
L2 stalk domains, the TIM-3 IgV domain,
and a broad distribution across the
FAS extracellular and intracellular death
domains. They found that the CD80 IgV
domain has three positively selected sites
in the CTLA-4 binding region and two in
the region where two CD80 IgV domains
interact in a back-to-back fashion to
form a noncovalent homodimer.
Surprisingly, many positively selected
sites of variation in CD86 are in the IgC
domain, which does not interact with
any known ligand. Previous work has
shown that Ig fusion proteins containing
the CD86 IgV domain alone were 100-
fold more potent at stimulating T cell
activation than those containing both IgV
and IgC domains (Rennert et al., 1997).
These results suggest an unappreciated
role of the CD86 IgC domain in attenu-ating activity of the IgV domain or interac-
tion of the IgC with another receptor. The
human KSHV (Karposi’s sarcoma-associ-
ated herpesvirus) encodes a protein,
MIR2, that interacts with the stalk and
transmembrane region of human CD86
and leads to the ubiquitination and degra-
dation of CD86.Molecular modeling of the
two hydrophobic amino acids positively
selected in primate CD86 transmembrane
domains shows that they interact with the
MIR2 transmembrane domain, whereas
the less hydrophobic amino acids present
in nonprimate genomes do not support
the interaction. These stronger interac-
tions in primates might modulate activity
of the viral ubiquitinase and represent
host adaption to viral pathogenesis.
One of the positively selected sites in
the PD-L1 IgV domain is adjacent to the
PD-1 binding surface. However, most of
the selected sites in both PD-L1 and
PD-L2 are in the stalk domain. The bind-
ing of PD-L1 and PD-L2 to PD-1 occurs
on the side of the IgV domain and requires
a somewhat horizontal positioning of the
proteins (Freeman, 2008). Positively
selected sites in the stalk might modulate
the capacity of the PD-1 ligand to bend
and assume an optimal positioning for
binding to PD-1 on another cell or the
capacity to form cis interactions with
PD-1 or CD80 on the same cell surface.
Alternatively, selected sites in the stalk8, June 27, 2013 ª2013 Elsevier Inc. 1083
